Patents by Inventor Ganesh M. Kishore

Ganesh M. Kishore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7335815
    Abstract: Methods are provided for producing plants and seeds having altered isoprenoid content and compositions. The methods find particular use in increasing the isoprenoid levels in plants, and in providing desirable isoprenoid compositions in a host plant cell.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: February 26, 2008
    Assignee: Calgene LLC
    Inventors: Albert Boronat, Narciso Campos, Ganesh M. Kishore
  • Patent number: 7195917
    Abstract: Methods and materials are disclosed for the inhibition and control of gibberellic acid levels. In particular, nucleic acid sequences of copalyl diphosphate synthase. 3-? hydroxylase, and 2-oxidase and additional nucleic acid sequences are disclosed. Gibberellic acid levels may be inhibited or controlled by preparation of a chimeric expression construct capable of expressing a RNA or protein product which suppresses the gibberellin biosynthetic pathway sequence, diverts substrates from the pathway or degrades pathway substrates or products. The sequence is preferably a copalyl diphosphate synthase sequence, a 3?-hydroxylase sequence, a 2-oxidase sequence, a phytoene synthase sequence, a C20-oxidase sequence, and a 2?,3?-hydroxylase sequence. Administration of a complementing agent, preferably a gibberellin or gibberellin precursor or intermediate restores bioactivity.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: March 27, 2007
    Assignee: Monsanto Technology LLC
    Inventors: Sherri M. Brown, Tedd D. Elich, Gregory R. Heck, Ganesh M. Kishore, Eugene W. Logusch, Sherry J. Logusch, Kenneth J. Piller, Sudabathula Rao, Joel E. Ream, Scott R. Baerson
  • Patent number: 7192753
    Abstract: Nucleic acid sequences, vectors, recombinant host cells, transgenic plants, and methods for their preparation are disclosed. The nucleic acid sequences encode threonine deaminase proteins that catalyze the conversion of threonine to ?-ketobutyrate. One or both of the amino acids at positions 447 and 481 of the encoded proteins can be selected from groups of particular amino acids. For example, the amino acid at position 447 can be alanine, isoleucine, valine, phenylalanine, tryptophan, or methionine. The amino acid at position 481 can be alanine, isoleucine, proline, phenylalanine, tryptophan, or methionine.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: March 20, 2007
    Assignee: Monsanto Technology LLC
    Inventors: Kenneth J. Gruys, Timothy A. Mitsky, Ganesh M Kishore, Steven C. Slater, Stephen R. Padgette, David M. Stark
  • Patent number: 7105730
    Abstract: This invention relates to the field of biotechnology, particularly as it pertains to the production of sterols in a variety of host systems particularly plants. More specifically, the invention relates to nucleic acid molecules encoding proteins and fragments of proteins associated with sterol and phytosterol metabolism as well as the encoded proteins and fragments of proteins and antibodies capable of binding to them. The invention also relates to methods of using the nucleic acid molecules, fragments of the nucleic acid molecules, proteins, and fragments of proteins. The invention also relates to cells, organisms, particularly plants, or seeds, or progeny of plants, that have been manipulated to contain increased levels or overexpress at least one sterol or phytosterol compound.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: September 12, 2006
    Assignee: Monsanto Technology L.L.C.
    Inventors: Balasulojini Karunanandaa, Jaehyuk Yu, Ganesh M. Kishore
  • Patent number: 7067647
    Abstract: Methods are provided for producing plants and seeds having altered isoprenoid content and compositions. The methods find particular use in increasing the isoprenoid levels in plants, and in providing desirable isoprenoid compositions in a host plant cell.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: June 27, 2006
    Assignee: Calgene LLC
    Inventors: Albert Boronat, Narciso Campos, Ganesh M. Kishore
  • Patent number: 6946588
    Abstract: Nucleic acid sequences, vectors, recombinant host cells, transgenic plants, and methods for their preparation are disclosed. The nucleic acid sequences encode threonine deaminase proteins that catalyze the conversion of threonine to ?-ketobutyrate. One or both of the amino acids at positions 447 and 481 of the encoded proteins can be selected from groups of particular amino acids. For example, the amino acid at position 447 can be alanine, isoleucine, valine, phenylalanine, tryptophan, or methionine. The amino acid at position 481 can be alanine, isoleucine, proline, phenylalanine, tryptophan, or methionine.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: September 20, 2005
    Assignee: Monsanto Technology LLC
    Inventors: Kenneth J. Gruys, Timothy A. Mitsky, Ganesh M. Kishore, Steven C. Slater, Stephen R. Padgette, David M. Stark
  • Patent number: 6822142
    Abstract: Disclosed are constructs comprising sequences encoding 3-hydroxy-3methylglutaryl-Coenzyme A reductase and at least one other sterol synthesis pathway enzyme. Also disclosed are methods for using such constructs to alter sterol production and content in cells, plants, seeds and storage organs of plants. Also provided are oils and compositions containing altered sterol levels produced by use of the disclosed constructs. Novel nucleotide sequences useful in the alteration of sterol production are also provided. Also provided are cells, plants, seeds and storage organs of plants comprising sequences encoding 3-hydroxy-3methylglutaryl-Coenzyme A reductase, at least one other sterol synthesis pathway enzyme and at least one tocopherol synthesis enzyme.
    Type: Grant
    Filed: June 20, 2001
    Date of Patent: November 23, 2004
    Assignee: Monsanto Company
    Inventors: Balasulojini Karunanandaa, Martha Post-Beittenmiller, Mylavarapu Venkatramesh, Ganesh M. Kishore, Gregory M. Thorne, John R. LeDeaux
  • Patent number: 6723897
    Abstract: Methods and materials are disclosed for the inhibition and control of gibberellic acid levels. In particular, nucleic acid sequences of copalyl diphosphate synthase, 3-&bgr; hydroxylase, and 2-oxidase and additional nucleic acid sequences are disclosed. Gibberellic acid levels may be inhibited or controlled by preparation of a chimeric expression construct capable of expressing antisense RNA which suppresses the gibberellin biosynthetic pathway sequence. The antisense sequence is the complement of a copalyl diphosphate synthase sequence, a 3&bgr;-hydroxylase sequence, or a C20-oxidase sequence. Administration of a complementing agent, preferably a gibberellin or gibberellin precursor or intermediate restores bioactivity.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: April 20, 2004
    Assignee: Monsanto Technology, LLC
    Inventors: Sherri M. Brown, Tedd D. Elich, Gregory R. Heck, Ganesh M. Kishore, Eugene W. Logusch, Sherry J. Logusch, Kenneth J. Piller, Sudabathula Rao, Joel E. Ream, Scott R. Baerson
  • Publication number: 20040073976
    Abstract: Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.
    Type: Application
    Filed: November 11, 2003
    Publication date: April 15, 2004
    Applicant: Monsanto Technology LLC
    Inventors: Gerard F. Barry, Nordine Cheikh, Ganesh M. Kishore
  • Patent number: 6716474
    Abstract: Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: April 6, 2004
    Assignee: Monsanto Technology LLC
    Inventors: Gerard F. Barry, Nordine Cheikh, Ganesh M. Kishore
  • Publication number: 20030233679
    Abstract: Methods and materials are disclosed for the inhibition and control of gibberellic acid levels. In particular, nucleic acid sequences of copalyl diphosphate synthase. 3-&bgr; hydroxylase, and 2-oxidase and additional nucleic acid sequences are disclosed. Gibberellic acid levels may be inhibited or controlled by preparation of a chimeric expression construct capable of expressing a RNA or protein product which suppresses the gibberellin biosynthetic pathway sequence, diverts substrates from the pathway or degrades pathway substrates or products. The sequence is preferably a copalyl diphosphate synthase sequence, a 3&bgr;-hydroxylase sequence, a 2-oxidase sequence, a phytoene synthase sequence, a C20-oxidase sequence, and a 2&bgr;,3&bgr;-hydroxylase sequence. Administration of a complementing agent, preferably a gibberellin or gibberellin precursor or intermediate restores bioactivity.
    Type: Application
    Filed: March 27, 2003
    Publication date: December 18, 2003
    Applicant: Monsanto Technology LLC.
    Inventors: Sherri M. Brown, Tedd D. Elich, Gregory R. Heck, Ganesh M. Kishore, Eugene W. Logusch, Sherry J. Logusch, Kenneth J. Piller, Sudabathula Rao, Joel E. Ream, Scott R. Baerson
  • Patent number: 6663906
    Abstract: Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: December 16, 2003
    Assignee: Monsanto Technology LLC
    Inventors: Gerard F. Barry, Nordine Cheikh, Ganesh M. Kishore
  • Patent number: 6653530
    Abstract: Methods are provided for producing plants and seeds having altered carotenoid, fatty acid and tocopherol compositions. The methods find particular use in increasing the carotenoid and tocopherol levels in oilseed plants, and in providing desirable high oleic acid seed oils.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: November 25, 2003
    Assignee: Calgene LLC
    Inventors: Christine K. Shewmaker, B. Ganesh Bhat, Mylavaraapu Venkatramesh, Shaukat H. Rangwala, Ganesh M. Kishore, Sekhar S. Boddupalli
  • Publication number: 20030150008
    Abstract: Disclosed are constructs comprising sequences encoding 3-hydroxy-3methylglutaryl-Coenzyme A reductase and at least one other sterol synthesis pathway enzyme. Also disclosed are methods for using such constructs to alter sterol production and content in cells, plants, seeds and storage organs of plants. Also provided are oils and compositions containing altered sterol levels produced by use of the disclosed constructs. Novel nucleotide sequences useful in the alteration of sterol production are also provided. Also provided are cells, plants, seeds and storage organs of plants comprising sequences encoding 3-hydroxy-3methylglutaryl-Coenzyme A reductase, at least one other sterol synthesis pathway enzyme and at least one tocopherol synthesis enzyme.
    Type: Application
    Filed: June 20, 2001
    Publication date: August 7, 2003
    Inventors: Balasulojini Karunanandaa, Martha Post-Beittenmiller, Mylavarapu Venkatramesh, Ganesh M. Kishore, Gregory M. Thorne, John R. LeDeaux
  • Publication number: 20030126641
    Abstract: Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.
    Type: Application
    Filed: June 6, 2002
    Publication date: July 3, 2003
    Applicant: Monsanto Technology LLC
    Inventors: Gerard F. Barry, Nordine Cheikh, Ganesh M. Kishore
  • Publication number: 20030028917
    Abstract: Genes and methods for optimizing levels of substrates employed in the biosynthesis of copolymers of 3-hydroxybutyrate (3HB) and 3-hydroxyvalerate (3HV) in plants and bacteria via manipulation of normal metabolic pathways using recombinant DNA techniques are provided. This is achieved through the use of a variety of wild-type and/or deregulated enzymes involved in the biosynthesis of aspartate family amino acids, and wild-type or deregulated forms of enzymes, such as threonine deaminase, involved in the conversion of threonine to P(3HB-co-3HV) copolymer endproduct. By these methods, enhanced levels of threonine, &agr;-ketobutyrate, propionate, propionyl-CoA, &bgr;-ketovaleryl-CoA, and &bgr;-hydroxyvaleryl-CoA are produced. Also provided are methods for the biological production of P(3HB-co-3HV) copolymers in plants and bacteria utilizing propionyl-CoA produced through a variety of engineered metabolic pathways.
    Type: Application
    Filed: August 30, 2001
    Publication date: February 6, 2003
    Applicant: Monsanto Technology, LLC.
    Inventors: Kenneth J. Gruys, Timothy A. Mitsky, Ganesh M. Kishore, Steven C. Slater, Stephen R. Padgette, David M. Stark
  • Publication number: 20020138875
    Abstract: Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.
    Type: Application
    Filed: August 6, 2001
    Publication date: September 26, 2002
    Applicant: Monsanto Technology, LLC.
    Inventors: Gerard F. Barry, Nordine Cheikh, Ganesh M. Kishore
  • Patent number: 6441277
    Abstract: Fructose-1,6-bisphosphate aldolase (FDA) is an enzyme reversibly catalyzing the reaction converting triosephosphate into fructose-1,6-bisphosphate. In the leaf, this enzyme is located in the chloroplast (starch synthesis) and the cytosol (sucrose biosynthesis). Transgenic plants were generated that express the E. coli fda gene in the chloroplast to improve plant yield by increasing leaf starch biosynthetic ability in particular and sucrose production in general. Leaves from plants expressing the fda transgene showed a significantly higher starch accumulation, as compared to control plants expressing the null vector, particularly early in the photoperiod, but had lower leaf sucrose. Transgenic plants also had a significantly higher root mass. Furthermore, transgenic potatoes expressing fda exhibited improved uniformity of solids.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: August 27, 2002
    Assignee: Monsanto Technology LLC
    Inventors: Gerard F. Barry, Nordine Cheikh, Ganesh M. Kishore
  • Patent number: RE38825
    Abstract: Genes encoding a glyphosate oxidoreductase enzyme are disclosed. The genes are useful in producing transformed bacteria and plants which degrade glyphosate herbicide as well as crop plants which are tolerant to glyphosate herbicide.
    Type: Grant
    Filed: July 7, 2000
    Date of Patent: October 11, 2005
    Assignee: Monsanto Technology LLC
    Inventors: Gerard F. Barry, Ganesh M. Kishore
  • Patent number: RE39247
    Abstract: Genes encoding Class II EPSPS enzymes are disclosed. The genes are useful in producing transformed bacteria and plants which are tolerant to glyphosate herbicide. Class II EPSPS genes share little homology with known, Class I EPSPS genes, and do not hybridize to probes from Class I EPSPS's. The Class II EPSPS enzymes are characterized by being more kinetically efficient than Class I EPSPS's in the presence of glyphosate. Plants transformed with Class II EPSPS genes are also disclosed as well as a method for selectively controlling weeds in a planted transgenic crop field.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: August 22, 2006
    Assignee: Monsanto Technology LLC
    Inventors: Gerard F. Barry, Ganesh M. Kishore, Stephen R. Padgette, William C. Stallings